Pediatr. praxi. 2021;22(1):62-66 | DOI: 10.36290/ped.2021.011

Acute cor pulmonale - current complications of cystic fibrosis

MUDr. Marcela Kreslová, Ph.D.1, MUDr. Adéla Skalická1, MUDr. Veronika Schwarzová1, MUDr. Zuzana Horková1, MUDr. Jiří Bejček, Ph.D.2, prof. MUDr. Josef Sýkora, Ph.D.1
1 Dětská klinika, Univerzita Karlova, Lékařská fakulta v Plzni, Fakultní nemocnice v Plzni
2 Klinika zobrazovacích metod, Univerzita Karlova, Lékařská fakulta v Plzni, Fakultní nemocnice v Plzni

Cystic fibrosis (CF) is a severe age-progressive autosomal recessively inherited multiorgan disease. The essence of the therapeutic approach to patients with CF is the effort to maximally compensate for the underlying disease, prevention and early treatment of complications. Acute exacerbations of the underlying disease or pneumonia are a common cause of respiratory deterioration, but it is also necessary to look for the rarer causes of dyspnea as a differential diagnosis. CF is one of the diseases with a higher risk of cardiovascular disease. The most common cardiovascular complication is cor pulmonale. Since adolescence, pulmonary embolism has been one of the causes of acute dyspnea, sometimes with an image of acute cor pulmonale, as evidenced by the presented case report of an 18.5-year-old girl.

Keywords: cystic fibrosis, children, cor pulmonale, pulmonary embolism, dyspnea.

Published: March 25, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kreslová M, Skalická A, Schwarzová V, Horková Z, Bejček J, Sýkora J. Acute cor pulmonale - current complications of cystic fibrosis. Pediatr. praxi. 2021;22(1):62-66. doi: 10.36290/ped.2021.011.
Download citation

References

  1. Pohunek P, Koťátko P, Tuková J, et al. Dětská pneumologie. Praha: Mladá fronta, a. s., 2018; 686 s.
  2. Český registr cystické fibrózy [Online] 10. 07. 2020. https://cfregistr.cz/.
  3. Konstan MW, McKone EF, Moss RB, et al. Assessment of safety and efficacy of long‑term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del‑CFTR mutation. Lancet Respir Med. 2017; 5: 107-118. Go to original source... Go to PubMed...
  4. Ratjen F, Hug C, Marigowda G, et al. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del‑CFTR: a randomised, placebo‑controlled, phase 3 trial. Lancet Respir Med. 2017; 5: 557-567. Go to original source... Go to PubMed...
  5. Sala M, Jain M. Tezacaftor for the treatment of cystic fibrosis. Expert Review of Respiratory Medicine 2018; 12 (9): 725-732. Go to original source... Go to PubMed...
  6. Taylor‑Cousar JL, Munck A, McKone EF. Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del. N Engl J Med. 2017; 377: 2013-2023. Go to original source... Go to PubMed...
  7. Kreslová M, Sýkorová A, Jehlička P, et al. Pletysmografické a biochemické metody jako nové možnosti neinvazivního hodnocení endotelové dysfunkce u dětí s CF - kombinovaný diagnostický přístup. Česko‑Slov Pediat 2019; 74 (7): 400-409.
  8. Vávrova V, et al. Cystická fibróza. Praha: Grada, 2006: 516 s.
  9. Flight WG, Bright‑Thomas RJ, Butterfield S, Jones AM, Webb AK. A therapeutic conundrum: recurrent cystic‑fibrosis‑related haemoptysis complicated by acute pulmonary embolism. Thora. 2012; 67: 931-932. Go to original source... Go to PubMed...
  10. Zaidi AU, Hutchins KK, Rajpurkar M. Pulmonary Embolism in Children. Frontiers in Pediatrics 2017; 5: 170. Go to original source... Go to PubMed...
  11. Thacker PG, Lee EY. Pulmonary Embolism in children. American Journal of Roentgenology 2015; 204: 1278-1288. Go to original source... Go to PubMed...
  12. Kritsaneepaiboon S, Lee EY, Zurakowski D, et al. MDCT Pulmonary Angiography Evaluation of Pulmonary Embolism in Children. American Journal of Roentgenology 2009; 192: 1246-1252. Go to original source... Go to PubMed...
  13. Homolka J. Cor pulmonale. Postgraduální medicína 2003; 6: 616-620.




Pediatrics for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.